Role of urokinase-type plasminogen activator in local immunotherapy.

  • Authors:
    • T Takeda
    • Y Ito
    • E Wakasugi
    • T Kobayashi
    • M Monden
  • View Affiliations

  • Published online on: March 1, 1998     https://doi.org/10.3892/or.5.2.329
  • Pages: 329-362
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We have previously reported that intratumoral injection of a mixture of OK-432 and fibrinogen (OK/fbg) is very effective for local immunotherapy of colorectal cancer, but has little influence on breast cancer, while addition of activated macrophages to OK/fbg (OK/fbg/mo) has a marked effect on breast cancer. In this study, we analyzed the role of urokinase-type plasminogen activator (uPA) in local immunotherapy. We found that uPA levels in breast cancer tissue were lower than in colorectal cancer tissue. Injection of OK-432 into breast cancers neither increased the uPA level nor caused tumor regression. Although OK/fbg injection caused an increase of uPA, tumor regression was restricted to the area around the injection site. With OK/fbg/mo however, uPA levels increased much more markedly and extensive tumor necrosis was observed in all cases. These findings suggest that uPA plays an important role in tumor regression during local immunotherapy.

Related Articles

Journal Cover

Mar-Apr 1998
Volume 5 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takeda T, Ito Y, Wakasugi E, Kobayashi T and Monden M: Role of urokinase-type plasminogen activator in local immunotherapy.. Oncol Rep 5: 329-362, 1998
APA
Takeda, T., Ito, Y., Wakasugi, E., Kobayashi, T., & Monden, M. (1998). Role of urokinase-type plasminogen activator in local immunotherapy.. Oncology Reports, 5, 329-362. https://doi.org/10.3892/or.5.2.329
MLA
Takeda, T., Ito, Y., Wakasugi, E., Kobayashi, T., Monden, M."Role of urokinase-type plasminogen activator in local immunotherapy.". Oncology Reports 5.2 (1998): 329-362.
Chicago
Takeda, T., Ito, Y., Wakasugi, E., Kobayashi, T., Monden, M."Role of urokinase-type plasminogen activator in local immunotherapy.". Oncology Reports 5, no. 2 (1998): 329-362. https://doi.org/10.3892/or.5.2.329